Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I

H Hasegawa, H Sawa, MJ Lewis, Y Orba, N Sheehy… - Nature medicine, 2006 - nature.com
H Hasegawa, H Sawa, MJ Lewis, Y Orba, N Sheehy, Y Yamamoto, T Ichinohe
Nature medicine, 2006nature.com
Adult T-cell leukemia-lymphoma (ATLL) is a group of T-cell malignancies caused by
infection with human T-lymphotropic virus type I (HTLV-I). Although the pathogenesis of
ATLL remains incompletely understood, the viral regulatory protein Tax is centrally involved
in cellular transformation. Here we describe the generation of HTLV-I Tax transgenic mice
using the Lck proximal promoter to restrict transgene expression to developing thymocytes.
After prolonged latency periods, transgenic mice developed diffuse large-cell lymphomas …
Abstract
Adult T-cell leukemia-lymphoma (ATLL) is a group of T-cell malignancies caused by infection with human T-lymphotropic virus type I (HTLV-I). Although the pathogenesis of ATLL remains incompletely understood, the viral regulatory protein Tax is centrally involved in cellular transformation. Here we describe the generation of HTLV-I Tax transgenic mice using the Lck proximal promoter to restrict transgene expression to developing thymocytes. After prolonged latency periods, transgenic mice developed diffuse large-cell lymphomas and leukemia with clinical, pathological and immunological features characteristic of acute ATLL. Transgenic mice were functionally immunocompromised and they developed opportunistic infections. Fulminant disease also developed rapidly in SCID mice after engraftment of lymphomatous cells from transgenic mice. Flow cytometry showed that the cells were CD4 and CD8, but CD44+, CD25+ and cytoplasmic CD3+. This phenotype is indicative of a thymus-derived pre–T-cell phenotype, and disease development was associated with the constitutive activation of NF-κB. Our model accurately reproduces human disease and will provide a tool for analysis of the molecular events in transformation and for the development of new therapeutics.
nature.com